• Austin, P.C. (2009) Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Statistics in Medicine, 28, 30833107.
  • Carson, K.R., Evens, A.M., Richey, E.A., Habermann, T.M., Focosi, D., Seymour, J.F., Laubach, J., Bawn, S.D., Gordon, L.I., Winter, J.N., Furman, R.R., Vose, J.M., Zelenetz, A.D., Mamtani, R., Raisch, D.W., Dorshimer, G.W., Rosen, S.T., Muro, K., Gottardi-Littell, N.R., Talley, R.L., Sartor, O., Green, D., Major, E.O. & Bennett, C.L. (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood, 113, 48344840.
  • Clarke, C.A., Undurraga, D.M., Harasty, P.J., Glaser, S.L., Morton, L.M. & Holly, E.A. (2006) Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study. Cancer Epidemiology, Biomarkers & Prevention, 15, 630638.
  • Coebergh, J.W., Janssen-Heijnen, M.L., Post, P.N. & Razenberg, P.P. (1999) Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993–1996. Journal Clinical Epidemiology, 52, 11311136.
  • Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235242
  • Coiffier, B., Thieblemont, C., Van Den Neste, E., Lepeu, G., Plantier, I., Castaigne, S., Lefort, S., Marit, G., Macro, M., Sebban, C., Belhadj, K., Bordessoule, D., Ferme, C. & Tilly, H. (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood, 116, 20402045.
  • Committee on the Assessment of the US Drug Safety System (2006) The future of drug safety: Promoting and proctecting the health of the public. (ed. by A. Baciu, K. Stratton & S.P. Burke), pp. 2. The National Academies Press, Washington, D.C.
  • Ennishi, D., Maeda, Y., Niitsu, N., Kojima, M., Izutsu, K., Takizawa, J., Kusumoto, S., Okamoto, M., Yokoyama, M., Takamatsu, Y., Sunami, K., Miyata, A., Murayama, K., Sakai, A., Matsumoto, M., Shinagawa, K., Takaki, A., Matsuo, K., Kinoshita, T. & Tanimoto, M. (2010) Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood, 116, 51195125.
  • Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Ferme, C., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., Gaulard, P., Salles, G., Bosly, A., Gisselbrecht, C., Reyes, F. & Coiffier, B. (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology, 23, 41174126.
  • Habermann, T.M., Weller, E.A., Morrison, V.A., Gascoyne, R.D., Cassileth, P.A., Cohn, J.B., Dakhil, S.R., Woda, B., Fisher, R.I., Peterson, B.A. & Horning, S.J. (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. Journal of Clinical Oncology, 24, 31213127.
  • Katsuya, H., Suzumiya, J., Sasaki, H., Ishitsuka, K., Shibata, T., Takamatsu, Y. & Tamura, K. (2009) Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma. Leukemia & Lymphoma, 50, 18181823.
  • Klein, J.P. & Moeschberger, M.L. (1997) Survival analysis: techniques for censored and truncated data. Springer-Verlag, New York.
  • Liu, X., Hong, X.N., Gu, Y.J., Wang, B.Y., Luo, Z.G. & Cao, J. (2008) Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma. Leukemia & Lymphoma, 49, 17781783.
  • Niitsu, N., Hagiwara, Y., Tanae, K., Kohri, M. & Takahashi, N. (2010) Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. Journal of Clinical Oncology, 28, 50975100.
  • Pfreundschuh, M., Trumper, L., Osterborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P.L., Stahel, R., Kvaloy, S., Shpilberg, O., Jaeger, U., Hansen, M., Lehtinen, T., Lopez-Guillermo, A., Corrado, C., Scheliga, A., Milpied, N., Mendila, M., Rashford, M., Kuhnt, E. & Loeffler, M. (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. The Lancet Oncology, 7, 379391.
  • Pfreundschuh, M., Schubert, J., Ziepert, M., Schmits, R., Mohren, M., Lengfelder, E., Reiser, M., Nickenig, C., Clemens, M., Peter, N., Bokemeyer, C., Eimermacher, H., Ho, A., Hoffmann, M., Mertelsmann, R., Trumper, L., Balleisen, L., Liersch, R., Metzner, B., Hartmann, F., Glass, B., Poeschel, V., Schmitz, N., Ruebe, C., Feller, A.C. & Loeffler, M. (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). The Lancet Oncology, 9, 105116.
  • Ram, R., Ben-Bassat, I., Shpilberg, O., Polliack, A. & Raanani, P. (2009) The late adverse events of rituximab therapy–rare but there!. Leukemia & Lymphoma, 50, 10831095.
  • Sehn, L.H., Donaldson, J., Chhanabhai, M., Fitzgerald, C., Gill, K., Klasa, R., MacPherson, N., O'Reilly, S., Spinelli, J.J., Sutherland, J., Wilson, K.S., Gascoyne, R.D. & Connors, J.M. (2005) Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. Journal of Clinical Oncology, 23, 50275033.
  • Seruga, B., Sterling, L., Wang, L. & Tannock, I.F. (2011) Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. Journal of Clinical Oncology, 29, 174185.
  • Starfield, B., Weiner, J., Mumford, L. & Steinwachs, D. (1991) Ambulatory care groups: a categorization of diagnoses for research and management. Health Services Research, 26, 5374.
  • Townsley, C.A., Selby, R. & Siu, L.L. (2005) Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. Journal of Clinical Oncology, 23, 31123124.